Table 5 ORs (95% CIs) for a 30% increment in baseline biomarker, and in year 1 to baseline biomarker ratio (change), based on cases occurring after year 1 and disease-specific controls, from the WHI estrogen plus progestin and estrogen-alone HT trials

Treatment^a

491

1.14 (0.79, 1.66)^b

1.16 (0.80, 1.68)

B2M baseline

1.22 (1.06, 1.40)

1.13 (0.95, 1.34)

B2M change

1.12 (0.96, 1.32)

Trial^a

1.09 (0.74, 1.59)

1.08 (0.74, 1.59)

Treatment^a

489

1.21 (0.83, 1.75)^b

1.24 (0.83, 1.84)

ORM1 baseline

1.00 (0.87, 1.16)

0.98 (0.82, 1.18)

ORM1 change

1.03 (0.87, 1.24)

Trial^a

1.03 (0.71, 1.51)

1.03 (0.71, 1.51)

Treatment^a

395

1.11 (0.73, 1.68)^b

1.11 (0.73, 1.68)

THBS1 baseline

0.95 (0.91, 1.00)

0.95 (0.89, 1.01)

THBS1 change

1.01 (0.95, 1.07)

Trial^a

0.96 (0.66, 1.39)

0.92 (0.60, 1.41)

Treatment^a

489

1.19 (0.82, 1.72)^b

1.26 (0.86 1.85)

CFD baseline

1.09 (0.95, 1.24)

0.93 (0.73 1.19)

CFD change

1.20 (0.94 1.52)

Trial^a

1.03 (0.73, 1.46)

1.06 (0.72 1.56)

Treatment^a

479

1.18 (0.81, 1.72)^b

0.96 (0.62, 1.49)

IGFBP1 baseline

1.01 (0.96, 1.06)

0.97 (0.90, 1.03)

IGFBP1 change

1.07 (0.99, 1.14)

Trial^a

0.98 (0.67, 1.44)

1.01 (0.69, 1.50)

Stroke

Modeled variables

N ^a

Biomarker values included

Baseline only

Baseline + change

Treatment^a

552

1.84 (1.28, 2.64)^b

1.87 (1.30, 2.70)

B2M baseline

1.10 (0.97, 1.23)

0.99 (0.86, 1.14)

B2M change

1.24 (1.03, 1.50)

Trial^a

1.10 (0.76, 1.59)

1.13 (0.78, 1.64)

Treatment^a

508

1.67 (1.14, 2.44)^b

1.57 (1.05, 2.33)

IGFBP2 baseline

1.09 (1.00, 1.18)

1.14 (1.00, 1.31)

IGFBP2 change

0.94 (0.84, 1.06)

Trial^a

1.09 (0.74, 1.60)

1.10 (0.75, 1.61)

Treatment^a

524

1.77 (1.22, 2.57)^b

1.74 (1.20, 2.53)

IGFBP4 baseline

1.18 (1.04, 1.34)

1.10 (0.93, 1.30)

IGFBP4 change

1.10 (0.94, 1.28)

Trial^a

1.08 (0.75, 1.30)

1.10 (0.75, 1.61)

Treatment^a

474

1.60 (1.08, 2.37)^b

1.60 (1.08, 2.37)

IGFBP6 baseline

0.99 (0.90, 1.09)

0.99 (0.89, 1.11)

IGFBP6 change

0.99 (0.91, 1.09,)

Trial^a

1.12 (0.75, 1.66)

1.11 (0.75, 1.66)

Treatment^a

526

1.74 (1.20, 2.51)^b

1.74 (1.20, 2.51)

HPX baseline

1.06 (0.88, 1.28)

1.07 (0.84, 1.36)

HPX change

0.99 (0.77, 1.29)

Trial^a

1.11 (0.76, 1.62)

1.11 (0.76, 1.62)